Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma 3Urogenital Neoplasms 2Prostatic Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Male Urogenital Diseases 2Genital Neoplasms, Male 2Lung Neoplasms 1Localized Prostate Cancer 1Genital Diseases, Male 1Genital Diseases 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

padeliporfin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Localized Prostate Cancer × padeliporfin × Clear all
NCT03315754 2024-12-20

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Steba Biotech S.A.

Phase 2 Active not recruiting
50 enrolled 8 charts
Genitourinary

Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡